Hematopoietic and Lymphoid Cell NeoplasmPhase 3BBT-IINCT04829539
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
A Phase 3 study testing Behavioral Intervention, Electronic Health Record Review and Quality-of-Life Assessment in people with Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by University of Rochester NCORP Research Base at 153 sites in United States.
Trial summary
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Behavioral Intervention, Electronic Health Record Review and Quality-of-Life Assessment
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 153 sitesUnited States
- Study dates
- 24 Jun 2021to 12 Apr 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be at least 18 years of age
- Be diagnosed with cancer (stage I, II, III, or IV) with a life expectancy of at least 12 months
- Be currently receiving any cancer treatment (surgery alone is excluded)
- Report sleep disturbance of 3 or greater on the sleep disturbance question: "Rate your sleep disturbance in the past 2 weeks on a scale from 0-10, 0 is no problems and 10 is having the most severe problems"
- Have a score of 2, 1, or 0 on the Eastern Cooperative Oncology Group (ECOG) performance status scale
- Be able to speak, understand and read English to participate in the study assessments and interventions
Who cannot join
- Have a clinical diagnosis of obstructive sleep apnea or restless leg syndrome (even if controlled)
- Be engaged in a formal cognitive behavioral therapy for insomnia program presently or in the past 30 days. Use of sleep medications are allowed
Trial locations and contacts
153 sites in 1 country.
153 sites in 1 country
United States153 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, 50023
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin, Missouri, 63011
Bronson Battle Creek
Battle Creek, Michigan, 49017
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Illinois CancerCare-Canton
Canton, Illinois, 61520
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Waverly Hematology Oncology
Cary, North Carolina, 27518
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Centralia Oncology Clinic
Centralia, Illinois, 62801
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Roper Hospital
Charleston, South Carolina, 29401
Charleston Oncology - Roper
Charleston, South Carolina, 29403
Lowcountry Hematology Oncology PA-North Charleston
Charleston, South Carolina, 29406
Bon Secours Saint Francis Hospital
Charleston, South Carolina, 29414
Charleston Oncology - Saint Francis
Charleston, South Carolina, 29414
Lowcountry Hematology Oncology PA-West Ashley
Charleston, South Carolina, 29414
Chesapeake Regional Medical Center
Chesapeake, Virginia, 23320
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa, 50325
Mount Carmel East Hospital
Columbus, Ohio, 43213
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mercy Hospital
Coon Rapids, Minnesota, 55433
Carle at The Riverfront
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Kaiser Permanente-Franklin
Denver, Colorado, 80205
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa, 50314
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Crossroads Cancer Center
Effingham, Illinois, 62401
Christiana Care - Union Hospital
Elkton, Maryland, 21921
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Hematology Oncology Associates of Fredericksburg Inc
Fredericksburg, Virginia, 22408
Unity Hospital
Fridley, Minnesota, 55432
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, 49503
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Urology Specialists of Nevada - Green Valley
Henderson, Nevada, 89074
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Mercy Hospital Joplin
Joplin, Missouri, 64804
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kingman Regional Medical Center
Kingman, Arizona, 86401
Kaiser Permanente-Rock Creek
Lafayette, Colorado, 80026
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
Urology Specialists of Nevada - Southwest
Las Vegas, Nevada, 89113
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
Urology Specialists of Nevada - Northwest
Las Vegas, Nevada, 89128
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, 89135
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Summerlin Hospital Medical Center
Las Vegas, Nevada, 89144
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
Kaiser Permanente-Lone Tree
Lone Tree, Colorado, 80124
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Centra Alan B Pearson Regional Cancer Center
Lynchburg, Virginia, 24501
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
Beebe South Coastal Health Campus
Millville, Delaware, 19967
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Monticello Cancer Center
Monticello, Minnesota, 55362
Knox Community Hospital
Mount Vernon, Ohio, 43050
Lowcountry Hematology Oncology PA-Mount Pleasant
Mt. Pleasant, South Carolina, 29464
Outer Banks Hospital
Nags Head, North Carolina, 27959
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112
University Medical Center New Orleans
New Orleans, Louisiana, 70112
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Licking Memorial Hospital
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Lake Regional Hospital
Osage Beach, Missouri, 65065
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Illinois CancerCare-Peru
Peru, Illinois, 61354
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania, 17901
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Corewell Health Reed City Hospital
Reed City, Michigan, 49677
Beebe Health Campus
Rehoboth Beach, Delaware, 19971
Valley Medical Center
Renton, Washington, 98055
Virginia Cancer Institute
Richmond, Virginia, 23229
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Memorial Health University Medical Center
Savannah, Georgia, 31404
Community Medical Center
Scranton, Pennsylvania, 18510
PeaceHealth United General Medical Center
Sedro-Woolley, Washington, 98284
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
VCU Community Memorial Health Center
South Hill, Virginia, 23970
Mercy Hospital Springfield
Springfield, Missouri, 65804
Mercy Hospital South
St Louis, Missouri, 63128
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235-1495
Missouri Baptist Sullivan Hospital
Sullivan, Missouri, 63080
BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri, 63127
Carle Cancer Center
Urbana, Illinois, 61801
PeaceHealth Southwest Medical Center
Vancouver, Washington, 98664
Ridgeview Medical Center
Waconia, Minnesota, 55387
Illinois CancerCare - Washington
Washington, Illinois, 61571
Saint Ann's Hospital
Westerville, Ohio, 43081
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Rice Memorial Hospital
Willmar, Minnesota, 56201
Shenandoah Oncology PC
Winchester, Virginia, 22601
Valley Health / Winchester Medical Center
Winchester, Virginia, 22601
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
About this study
Official title: Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researchers determine which treatment works better in reducing insomnia, BBT-CI or HEAL.
Read the detailed description
PRIMARY OBJECTIVE:
- Determine the efficacy of BBT-CI compared to HEAL for treating insomnia as measured by the Insomnia Severity Index (ISI) at post-intervention.
SECONDARY OBJECTIVE:
- Determine the efficacy of BBT-CI compared to HEAL for improving sleep efficiency as measured via actigraphy at post-intervention.
MECHANISTIC OBJECTIVE:
- Examine the efficacy of BBT-CI compared to HEAL for regulating circadian rhythms as measured via actigraphy (i.e., Mesor, Acrophase, Amplitude, I<O dichotomy index).
EXPLORATORY OBJECTIVES:
- Examine potential moderators of BBT-CI effects on insomnia (ISI). II. Examine potential mediators of BBT-CI effects on insomnia (ISI). III. Determine the efficacy of BBT-CI compared to HEAL for treating insomnia as measured by the Insomnia Severity Index at the 6-month follow-up.
IV. Determine the efficacy of BBT-CI compared to HEAL for improving sleep efficiency as measured via actigraphy at the 6-month follow-up.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (BBT-CI): Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
GROUP II (HEAL): Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
After completion of study, patients are followed for up to 6 months.
- Being tested
- Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioral InterventionBehavioural
Also called Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy
Receive BBT-CI
Behavioral InterventionBehavioural
Also called Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy
Receive HEAL
Electronic Health Record ReviewOther
Ancillary studies
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Group I (BBT-CI) | Experimental | Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions. Receives: Behavioral: Behavioral Intervention; Other: Electronic Health Record Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
| Group II (HEAL) | Active comparator | Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions. Receives: Behavioral: Behavioral Intervention; Other: Electronic Health Record Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Insomnia Severity Index (ISI)
Will evaluate the mean between arm difference in ISI score change from time point baseline to post-intervention. To assess this, will use analysis of covariance model with ISI at post-intervention as the outcome, study arm (group) as a fixed effect and baseline ISI as a covariate. Will test baseline group interaction.
Measured: post intervention
Secondary outcomes (2)
Sleep efficiency
Will be measured via actigraphy.
Measured: post intervention
Circadian phenomena
Circadian phenomena will be measured via actigraphy (Mesor, Acrophase, Amplitude, I < O dichotomy index).
Measured: Up to 6 months post intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2021
- Study start24 Jun 2021
- Primary completion14 Oct 2026 (estimated)
- Study completion12 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Rochester NCORP Research Base
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Karen Mustian, University of Rochester
- Investigators
- Oxana Palesh, PhD, Principal investigator, Massey Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04829539
- Sponsor's protocol ID
- URCC-19185
- Other IDs
- R01CA214647, R01CA239714, UG1CA189961, NCI-2020-07175, URCC19185, URCC-19185, URCC-19185
- Acronym
- BBT-II
- Status last verified
- Apr 2026
- First submitted
- 11 Mar 2021
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Cai Z, Tang Y, Liu C, Li H, Zhao G, Zhao Z, Zhang B. Cognitive behavioural therapy for insomnia in people with cancer. Cochrane Database Syst Rev. 2025 Oct 31;10(10):CD015176. doi: 10.1002/14651858.CD015176.pub2.
PubMed 41170811
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
- ClinicalTrials.gov ID
- NCT04829539
- Acronym / sponsor ID
- BBT-II / URCC-19185
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University of Rochester NCORP Research BaseUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 24 Jun 2021 (actual)
- Primary completion
- 14 Oct 2026 (estimated)
- Study completion
- 12 Apr 2027 (estimated)
- First posted
- 2 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researchers determine which treatment works better in reducing insomnia, BBT-CI or HEAL.
Detailed description
PRIMARY OBJECTIVE:
- Determine the efficacy of BBT-CI compared to HEAL for treating insomnia as measured by the Insomnia Severity Index (ISI) at post-intervention.
SECONDARY OBJECTIVE:
- Determine the efficacy of BBT-CI compared to HEAL for improving sleep efficiency as measured via actigraphy at post-intervention.
MECHANISTIC OBJECTIVE:
- Examine the efficacy of BBT-CI compared to HEAL for regulating circadian rhythms as measured via actigraphy (i.e., Mesor, Acrophase, Amplitude, I<O dichotomy index).
EXPLORATORY OBJECTIVES:
- Examine potential moderators of BBT-CI effects on insomnia (ISI). II. Examine potential mediators of BBT-CI effects on insomnia (ISI). III. Determine the efficacy of BBT-CI compared to HEAL for treating insomnia as measured by the Insomnia Severity Index at the 6-month follow-up.
IV. Determine the efficacy of BBT-CI compared to HEAL for improving sleep efficiency as measured via actigraphy at the 6-month follow-up.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (BBT-CI): Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
GROUP II (HEAL): Patients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions.
After completion of study, patients are followed for up to 6 months.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I (BBT-CI) | Experimental | Behavioral: Behavioral Intervention, Other: Electronic Health Record Review, Other: Quality-of-Life Assessment, Other: Questionnaire AdministrationPatients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions. |
| Group II (HEAL) | Active comparator | Behavioral: Behavioral Intervention, Other: Electronic Health Record Review, Other: Quality-of-Life Assessment, Other: Questionnaire AdministrationPatients complete face to face/video sessions with a trained staff member. Patients also complete phone sessions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Be at least 18 years of age
- Be diagnosed with cancer (stage I, II, III, or IV) with a life expectancy of at least 12 months
- Be currently receiving any cancer treatment (surgery alone is excluded)
- Report sleep disturbance of 3 or greater on the sleep disturbance question: "Rate your sleep disturbance in the past 2 weeks on a scale from 0-10, 0 is no problems and 10 is having the most severe problems"
- Have a score of 2, 1, or 0 on the Eastern Cooperative Oncology Group (ECOG) performance status scale
Key exclusion criteria (2 listed)
- Have a clinical diagnosis of obstructive sleep apnea or restless leg syndrome (even if controlled)
- Be engaged in a formal cognitive behavioral therapy for insomnia program presently or in the past 30 days. Use of sleep medications are allowed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioral InterventionAlso: Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior TherapyReceive BBT-CI | Behavioural | Group I (BBT-CI) |
| Behavioral InterventionAlso: Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior TherapyReceive HEAL | Behavioural | Group II (HEAL) |
| Electronic Health Record ReviewAncillary studies | Other | Group I (BBT-CI), Group II (HEAL) |
| Quality-of-Life AssessmentAlso: Quality of Life AssessmentAncillary studies | Other | Group I (BBT-CI), Group II (HEAL) |
| Questionnaire AdministrationAncillary studies | Other | Group I (BBT-CI), Group II (HEAL) |
Primary outcome
Insomnia Severity Index (ISI)
Time frame: post intervention
Will evaluate the mean between arm difference in ISI score change from time point baseline to post-intervention. To assess this, will use analysis of covariance model with ISI at post-intervention as the outcome, study arm (group) as a fixed effect and baseline ISI as a covariate. Will test baseline group interaction.
2 secondary outcomes
Sleep efficiency
Time frame: post intervention
Circadian phenomena
Time frame: Up to 6 months post intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Derived from this study: PubMed 41170811Cai Z, Tang Y, Liu C, Li H, Zhao G, Zhao Z, Zhang B. Cognitive behavioural therapy for insomnia in people with cancer. Cochrane Database Syst Rev. 2025 Oct 31;10(10):CD015176. doi: 10.1002/14651858.CD015176.pub2.
Related trials for Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oxana Palesh, PhD principal investigator
Massey Cancer Center
153 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Behavioral Intervention, Electronic Health Record Review and Quality-of-Life Assessment in people with Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by University of Rochester NCORP Research Base at 153 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 153 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Insomnia Severity Index (ISI) (time frame: post intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04829539, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.